Luis Fein
About
Luis Fein is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Luis Fein has authored 52 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Luis Fein's work include Cancer Treatment and Pharmacology (21 papers), Prostate Cancer Treatment and Research (12 papers) and HER2/EGFR in Cancer Research (11 papers). Luis Fein is often cited by papers focused on Cancer Treatment and Pharmacology (21 papers), Prostate Cancer Treatment and Research (12 papers) and HER2/EGFR in Cancer Research (11 papers). Luis Fein collaborates with scholars based in Argentina, United States and United Kingdom. Luis Fein's co-authors include Andrew Protheroe, Susan Feyerabend, Kim N., B. Yа. Alekseev, Mustafa Özgüroğlu, Karim Fizazi, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, Dingwei Ye and Peter De Porre and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.
In The Last Decade
Luis Fein
51 papers receiving 3.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Luis Fein Argentina | 18 | 2.6k | 1.7k | 1.3k | 727 | 625 | 52 | 3.8k | ||
| Bryan Selby United States | 5 | 3.3k 1.3× | 917 0.6× | 1.0k 0.8× | 1.1k 1.5× | 344 0.6× | 11 | 3.7k | ||
| Mary Ellen Taplin United States | 16 | 4.2k 1.6× | 1.6k 0.9× | 1.0k 0.8× | 962 1.3× | 326 0.5× | 27 | 5.1k | ||
| Susan Feyerabend United Kingdom | 21 | 3.2k 1.2× | 1.0k 0.6× | 1.1k 0.9× | 1.0k 1.4× | 165 0.3× | 71 | 3.9k | ||
| Youn C. Park United States | 11 | 2.7k 1.0× | 785 0.5× | 805 0.6× | 775 1.1× | 175 0.3× | 20 | 3.1k | ||
| J Horti Hungary | 9 | 3.6k 1.4× | 1.6k 1.0× | 1.1k 0.8× | 1.2k 1.6× | 256 0.4× | 17 | 4.6k | ||
| Peter De Porre United States | 26 | 2.5k 1.0× | 761 0.5× | 854 0.7× | 893 1.2× | 231 0.4× | 91 | 3.4k | ||
| Mohammad Hirmand United States | 18 | 4.6k 1.8× | 1.3k 0.8× | 1.6k 1.3× | 1.6k 2.3× | 485 0.8× | 38 | 5.2k | ||
| Matthew M. Cooney United States | 24 | 3.6k 1.4× | 1.8k 1.1× | 1.1k 0.9× | 1.1k 1.6× | 173 0.3× | 86 | 5.2k | ||
| Simon Chowdhury United Kingdom | 29 | 4.0k 1.5× | 1.4k 0.8× | 1.4k 1.1× | 1.3k 1.8× | 308 0.5× | 199 | 5.1k |
Countries citing papers authored by Luis Fein
Since
Specialization
Citations
This map shows the geographic impact of Luis Fein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Fein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Fein more than expected).
Fields of papers citing papers by Luis Fein
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Luis Fein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Fein. The network helps show where Luis Fein may publish in the future.
Co-authorship network of co-authors of Luis Fein
This figure shows the co-authorship network connecting the top 25 collaborators of Luis Fein. A scholar is included among the top collaborators of Luis Fein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luis Fein. Luis Fein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Menzies, Alexander M., Georgina V. Long, Hussein A. Tawbi, et al.. (2024). POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis. Neuro-Oncology Advances. 6(1). vdae033–vdae033.
2.
Borrego, Manuel Ruíz, Yen‐Shen Lu, Yeon Hee Park, et al.. (2024). SGLT2 inhibition improves PI3Kα inhibitor–induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials. Breast Cancer Research and Treatment. 208(1). 111–121.
3.
Fein, Luis, Nicolas Lazaretti, John R. Benfield, et al.. (2023). Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate. Clinical Drug Investigation. 43(9). 699–706.
4.
Rugo, Hope S., Francisco Barrios, Suyapa Bejarano, et al.. (2022). Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology. 41(1). 65–74.
5.
Tutt, Andrew, John J. Garber, R.D. Gelber, et al.. (2022). VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. Annals of Oncology. 33(5). 566–568.
6.
Choueiri, Toni K., Tom Powles, Laurence Albigès, et al.. (2022). LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). Annals of Oncology. 33. S1430–S1431.
7.
Matsubara, Nobuaki, Kim N., Mustafa Özgüroğlu, et al.. (2019). Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. European Urology. 77(4). 494–500.
8.
Fizazi, Karim, Luis Fein, Nobuaki Matsubara, et al.. (2017). Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine. 377(4). 352–360.
9.
Fein, Luis, Yi‐Long Wu, Lecia V. Sequist, et al.. (2016). P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6. Journal of Thoracic Oncology. 11(10). S202–S203.
10.
Gómez, Henry, Silvia P. Neciosup, C. Tosello, et al.. (2015). A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study). Clinical Breast Cancer. 16(1). 38–44.
11.
Rapoport, Bernardo L., Daniel T. T. Chua, Allen Poma, et al.. (2015). Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Supportive Care in Cancer. 23(11). 3281–3288.
12.
Jassem, Jacek, Luis Fein, Mark Karwal, et al.. (2011). Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: A pooled subset analysis of two phase III studies. The Breast. 21(1). 89–94.
13.
Barrios, Carlos H., David Hernández‐Barajas, Michael P. Brown, et al.. (2011). Phase II trial of continuous once‐daily dosing of sunitinib as first‐line treatment in patients with metastatic renal cell carcinoma. Cancer. 118(5). 1252–1259.
14.
Hortobágyi, Gabriel N., Henry Gómez, Rubi K. Li, et al.. (2010). Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Research and Treatment. 122(2). 409–418.
15.
Buzaid, Antônio C., Sérgio D. Simon, Luis Fein, et al.. (2010). Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: The LABEL Study. Clinical Colorectal Cancer. 9(5). 282–289.
16.
Seidman, Andrew D., Adam Brufsky, Rafat Ansari, et al.. (2010). Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology. 22(5). 1094–1101.
17.
Pivot, Xavier, Rubi K. Li, Eva Thomas, et al.. (2009). Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. European Journal of Cancer. 45(17). 2940–2946.
18.
Blajman, C., Luis Fein, Matías Chacón, et al.. (2008). Pharmacokinetic equivalence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in a clinical study of patients with advanced cancer.. Cancer Research. 68. 207–207.
19.
Pezzotto, Stella Maris, et al.. (2006). Gallbladder cancer: surgical results after cholecystectomy in 25 patients with lamina propria invasion and 26 patients with muscular layer invasion. Journal of Hepato-Biliary-Pancreatic Surgery. 13(6). 562–566.
20.
Kaufmann, M., Emilio Bajetta, Luis Fein, et al.. (2000). Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. European Journal of Cancer. 36. 86–87.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Bryan Selby Breakdown of academic impact, for papers by Mary Ellen Taplin Breakdown of academic impact, for papers by Susan Feyerabend Breakdown of academic impact, for papers by Youn C. Park Breakdown of academic impact, for papers by J Horti Breakdown of academic impact, for papers by Peter De Porre Breakdown of academic impact, for papers by Mohammad Hirmand Breakdown of academic impact, for papers by Matthew M. Cooney Breakdown of academic impact, for papers by Simon Chowdhury